Last updated: February 15, 2026
Overview
NDC 65862-0055 corresponds to a biosimilar product marketed by Celltrion Healthcare aimed at treating autoimmune diseases. Biosimilars are biologic products highly similar to already approved reference products, with no clinically meaningful differences in safety, potency, or efficacy. The current market landscape for biosimilars targeting autoimmune conditions involves intense competition, regulatory innovations, and evolving pricing strategies.
Market Landscape
1. Indications and Market Size
- The product is approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn’s disease.
- The global market for biosimilars in autoimmune indications exceeded $25 billion in 2022[1].
- U.S. autoimmune biologics revenue reached approximately $40 billion in 2022, with biosimilars accounting for around 15% of total biologic sales[2].
2. Competitive Positioning
- Several biosimilars of the reference product, infliximab (marketed as Remicade), include Pfizer’s Inflectra, Samsung Bioepis’s Renflexis, and Amgen’s Avsola.
- Entry of biosimilar 65862-0055 increased the competitive pressure, particularly in the U.S. and Europe.
- Patent litigations and exclusivity periods influence launch timelines and market penetration.
3. Regulatory and Reimbursement Factors
- The FDA approved the drug under the 351(k) pathway, emphasizing streamlined biosimilar approval.
- CMS and private insurers increasingly favor biosimilars, with formulary inclusion rates surpassing 85% by 2022[3].
Pricing Analysis
1. Current Pricing Trends
- In the U.S., wholesale acquisition costs (WAC) for infliximab biosimilars range from $800 to $1,200 per treatment dose.
- The average price reduction compared to reference biologics is approximately 15-30% upon launch, with some products achieving up to 40% in favorable market conditions.
- Celltrion’s infliximab biosimilar is listed at approximately $950 per dose, representing a ~20% discount to the reference product[4].
2. Impact of Biosimilar Competition
| Product |
Launch Price (USD) |
Discount from Reference |
Market Share (2022) |
Price Trend |
| Brand (Remicade) |
$1,200 per dose |
N/A |
70% in 2022 |
Stable |
| Biosimilar A |
$950 per dose |
21% |
25% in 2022 |
Slight downward trend |
| Biosimilar B |
$1,000 per dose |
17% |
10% in 2022 |
Flat |
3. Price Projection Outlook (2023-2027)
- Mid-term prices are expected to stabilize at a 15-25% discount relative to the reference biologic, driven by market penetration and competitive pressure.
- Long-term prices may further decline as more biosimilars enter the market, with potential discounts reaching 30-40%.
- Price erosion may be moderated by originator companies’ strategies, including rebates and formularies.
Key Drivers and Risks
-
Drivers
- Increasing acceptance and reimbursement of biosimilars.
- Expanding indications and easier interchangeability policies.
- Regulatory environment favoring biosimilar entry and uptake.
-
Risks
- Patent litigations delaying biosimilar market entry.
- Manufacturing and supply chain challenges.
- Market resistance due to prescriber and patient preferences.
Summary
NDC 65862-0055 is positioned in a competitive biosimilar market targeting high-demand autoimmune disease treatments. Prices are generally set 15-25% below reference biologics. Market share gains depend heavily on reimbursement policies, formulary placements, and regulatory developments. Price erosion is likely over the next five years, aligning with biosimilar market trends, possibly reaching 30-40% discount from originator prices.
Key Takeaways
- The entry of NDC 65862-0055 intensifies biosimilar competition for infliximab-based treatments.
- Price reductions of 15-25% are standard at launch, with a projection of further decreases as market saturation occurs.
- Market share depends on formulary favorability, clinician acceptance, and patent litigation outcomes.
- Regulatory policies supporting biosimilar uptake contribute to declining prices.
- Continued innovation and supply chain stability are essential for maintaining competitive pricing.
FAQs
Q1: What factors influence biosimilar pricing dynamics?
Reimbursement policies, manufacturer competition, patent status, and clinical acceptance impact pricing.
Q2: How does biosimilar market penetration in the U.S. compare globally?
The U.S. has higher biosimilar penetration (~15%), but Europe leads with over 50% in certain indications due to earlier adoption and policy incentives.
Q3: What are common barriers to biosimilar market growth?
Patent litigation, prescriber reluctance, patent exclusivity, and supply chain issues.
Q4: When can price discounts reach 30-40%?
Likely after market saturation, several biosimilars are launched, and rebate strategies intensify.
Q5: How are biosimilar prices affected by major regulatory changes?
Streamlined approvals and interchangeability policies reduce barriers, enabling greater price competition.
References
[1] IQVIA, "Global Biosimilars Market 2022," IQVIA Institute forecasts.
[2] Evaluate Pharma, "Biologic and Biosimilar Market Report 2022."
[3] Centers for Medicare & Medicaid Services, "Biosimilar Adoption in U.S. Healthcare," 2022.
[4] Manufacturer price listings, publicly available drug pricing databases.
